S
Sohan Deshpande
Researcher at York University
Publications - 29
Citations - 3256
Sohan Deshpande is an academic researcher from York University. The author has contributed to research in topics: Systematic review & Cost effectiveness. The author has an hindex of 16, co-authored 26 publications receiving 2616 citations.
Papers
More filters
Journal ArticleDOI
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
Hedwig M. Blommestein,Nigel Armstrong,Steve Ryder,Sohan Deshpande,Gill Worthy,Caro Noake,Rob Riemsma,Jos Kleijnen,Jos Kleijnen,Johan L. Severens,Maiwenn Al +10 more
TL;DR: The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with myelodysplastic syndromes associated with deletion 5q cytogenetic abnormality, and the NICE’s subsequent decisions are described.
Journal ArticleDOI
Response to Letter to the Editor Regarding "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal".
Bram Ramaekers,Rob Riemsma,Florian Tomini,Thea van Asselt,Sohan Deshpande,Steven Duffy,Nigel Armstrong,Johan L. Severens,Jos Kleijnen,Manuela A. Joore +9 more
TL;DR: This paper responds to the aspects highlighted by Reifsnider et al.
Journal ArticleDOI
Clinically inappropriate post hoc exclusion of study participants from test accuracy calculations: the ROMA score, an example from a recent NICE diagnostic assessment.
Shona H. Lang,Nigel Armstrong,Sohan Deshpande,Bram Ramaekers,Sabine Grimm,Shelley de Kock,Jos Kleijnen,Marie Westwood +7 more
TL;DR: The results illustrate the potential consequences of inappropriate population selection in diagnostic studies; women with non-epithelial ovarian cancers or non-ovarian primaries, and those borderline tumours may be disproportionately represented among those with false negative, ‘low risk’ ROMA scores.
Journal ArticleDOI
Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes: Systematic Literature Review
Ralph V. Boccia,Sohan Deshpande,C.M. von Wilamowitz-Moellendorff,R. Raorane,S. Klijn,Hong Xiao,Aylin Yucel +6 more
TL;DR: A systematic literature review (SLR) was conducted to assess quantitative associations between prognostic factors and response to treatment with erythropoiesis-stimulating agents (ESAs) in patients with lower-risk myelodysplastic syndromes as discussed by the authors .